Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-12-01 pm EST
181.48 USD   +3.17%
04:34aCornell University : Experimental vaccines offer long-term protection against severe COVID
AQ
11/30Moderna exec says COVID trials improved diversity recruiting
RE
11/30Insider Sell: Moderna
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Moderna

08/11/2022 | 05:39pm EST


ę MT Newswires 2022
All news about MODERNA, INC.
04:34aCornell University : Experimental vaccines offer long-term protection against severe COVID
AQ
11/30Moderna exec says COVID trials improved diversity recruiting
RE
11/30Insider Sell: Moderna
MT
11/30Insider Sell: Moderna
MT
11/30Britain is little better prepared for future pandemics - Former UK vaccine chief
RE
11/28Insider Sell: Moderna
MT
11/28Insider Sell: Moderna
MT
11/24Researchers test mRNA technology for universal flu vaccine
RE
11/23B.C. study finds low but increased risk of myocarditis after 2nd Moderna COVID shot
AQ
11/22US renews push for COVID boosters as data show they protect
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 089 M - -
Net income 2022 8 897 M - -
Net cash 2022 12 022 M - -
P/E ratio 2022 8,16x
Yield 2022 -
Capitalization 67 581 M 67 581 M -
EV / Sales 2022 2,91x
EV / Sales 2023 6,14x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 175,91 $
Average target price 211,25 $
Spread / Average Target 20,1%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-28.55%67 581
IQVIA HOLDINGS INC.-21.83%40 495
LONZA GROUP AG-33.17%38 281
ALNYLAM PHARMACEUTICALS, INC.29.88%27 139
SEAGEN INC.-21.72%22 538
CELLTRION, INC.-11.11%18 418